Amgen Reports Phase 3 Trial Comparing Vectibix to Erbitux Meets Primary Endpoint Of Non-Inferiority Of Overall Survival

Amgen (NASDAQ: AMGN ) today announced detailed results from the Phase 3 ASPECCT ('763) trial comparing Vectibix® (panitumumab) to Erbitux® (cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer in patients who have not responded to chemotherapy. The study met its primary endpoint, demonstrating that panitumumab was non-inferior